Discover the key updates from the newly released PCWG4 guidelines for prostate cancer trials in this imaging-focused webinar led by co-author, Dr. Phillip H. Kuo.
Learn how emerging imaging advancements, especially the expanded role of PSMA PET, are reshaping trial design, conduct, and analysis. In just 30 minutes, Dr. Kuo breaks down what’s new, what’s changing, and what it means for researchers and clinicians working to improve outcomes in prostate cancer.
Presenter:
Phillip H. Kuo, MD, PhD, FACR, Consultant, Perceptive Imaging
Dr. Kuo is an internationally recognized physician-scientist. He played a pivotal role in the landmark VISION trial with Endocyte and Novartis, leading imaging eligibility design and quantitative PSMA PET analytics using AI. His academic career spans molecular imaging, MR, and radiopharmaceutical development, with notable contributions in dopaminergic imaging and neuro-oncologic theranostics. Dr. Kuo is deeply engaged in Alzheimer’s research, shaping appropriate use criteria and procedural guidelines. He has authored over 140 peer-reviewed publications and continues to advance innovation in imaging and therapeutic development globally.
Δ
